On September 15, 2023, Robert Foster, the CEO, CSO, and Director of Hepion Pharmaceuticals Inc (NASDAQ:HEPA), made a significant insider purchase of 1,600 shares of the company's stock.

In addition, Edison-based Hepion said CEO and Director Robert Foster resigned from his positions for personal reasons, effective immediately.

“Data from the first of these two poster presentations serve to demonstrate the value of machine learning,” commented Robert Foster, PharmD, PhD, CEO of Hepion. “Using multi-omics, our ...

In December, Hepion CEO and Director Robert Foster resigned from his positions for personal reasons and Chief Financial Officer John Cavan was appointed interim CEO.

Hepion Pharmaceuticals appoints Dr. Kaouthar Lbiati as interim CEO as it pivots to diagnostic tests for celiac, COVID, liver cancer and more.

About Hepion Pharmaceuticals The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes.

In addition, the Company announced that Dr. Robert Foster, the Company’s CEO, resigned from the Company as CEO and director for personal reasons, effective immediately.

As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 426897302. The reverse stock split was previously approved by Hepion stockholders at the ...

We believe rencofilstat may be well-positioned to offer a unique approach to treating both NASH and HCC, as these diseases are often intertwined,” commented Hepion’s CEO, Robert Foster.

Dr. Robert Foster, Hepion’s CEO remarked, “As our Phase 2b NASH clinical trial progresses, we continue our nonclinical research on cancer and other fibrotic indications such as IPF with the ...

"We appreciate the support of both the State of New Jersey and the Province of Alberta to support innovation within their respective business communities," said Robert Foster, PharmD, PhD, Hepion ...

--Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on Artificial Intelligence- driven therapeutic drug development for the treatment of fibrotic diseases, including ...